Patients with KRASG12C mutated-non-small cell lung cancer who were treated with glecirasib, a KRASG12C-inhibitor, experienced promising outcomes according to new findings presented during an April 30 session of the American Society of Clinical Oncology Plenary Series.
The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.
